Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on LinkedIn:
“Happy to share our editorial in JAMA Oncology with Dr. Harold Burstein on the OS analysis of the SONIA trial.
This trial challenged the dogma that ‘the sooner, the better‘ is always the optimal strategy for drug sequencing in patients with metastatic breast cancer
Lessons:
- Studies should plan to include analyses of OS and rigorously document the extent and adequacy of postprogression treatment.
- Trials intended to move drugs up the ladder from second or third line to first line should mandate crossover therapy.
- The SONIA experience underscores the power of good clinical judgment presumably informed by patient preference.
Title: Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
Authors: Noor Wortelboer, Annemiek van Ommen-Nijhof, Inge R. Konings
Read The Full Article
Title: Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?
Authors: Carmine Valenza, Harold J. Burstein
Read The Full Article
Other articles about CDK4/6 on OncoDaily.